Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
As Israeli Firm Publishes Full-Year Results
Executive Summary
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.
You may also be interested in...
Amphastar’s Forteo ANDA Hit With CRL As Wait Goes On
Amphastar will not be receiving approval in 2022 for its proposed generic version of Eli Lilly’s Forteo (teriparatide) peptide for the treatment of osteoporosis, after the FDA told the company it could not issue an approval at this stage.
Leaner Teva Bolsters Margins With 2022 Expected To Be Trough Year
Keeping a keen eye on costs through a multi-pronged strategy allowed Teva to bolster its margins and direct cash flow towards debt in 2021. But revenues declined and 2022 is set to be another bumpy year for the Israeli giant’s top line.
Teva Comments On Sandoz Implications Amid Strategic Review
Teva CEO Kåre Schultz has weighed in on Novartis’ plans to conduct a strategic review for its Sandoz unit, while also airing frustrations over continued delays for complex products in the US.